Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-01-24
1999-10-12
Grimes, Eric
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 435 691, A61K 3800, C07K 1447
Patent
active
059655283
ABSTRACT:
Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.
REFERENCES:
patent: 4692332 (1987-09-01), McMichael
patent: 4877610 (1989-10-01), McMichael
patent: 4966753 (1990-10-01), McMichael
patent: 4970071 (1990-11-01), McMichael
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5130415 (1992-07-01), Tecce et al.
patent: 5206153 (1993-04-01), Tamaoki et al.
patent: 5365948 (1994-11-01), McMichael
patent: 5384250 (1995-01-01), Murgita
Abramsky, et al., Journal of Neuroimmunology, 2:1-7 (1982).
Abramsky et al., Annals New York Academy of Sciences, pp. 108-115 (1983).
Aoyagi et al., Gann, 75:809-815 (1984).
Biddle et al., Breast Cancer Research and Treatment, 10:279-286 (1897).
Boismenu et al., Life Sciences, 43:673-681 (1988).
Brenner et al., Annals of the New York Academy of Sciences, vol. 377 pp. 208-221 (1981).
Brenner et al., Proc. Natl. Acad. Sci. USA, 77:3635-3639 (1980).
Brenner et al., Immunology Letters, 3:163-167 (1981).
Buamah et al., Clinica Chimica Aca., 139:313-316 (1984).
Buschman et al., Journal of Neuroimmunology 13:315-330 (1987).
Cohen et al., Scand. J. Immunol. 23:211-223 (1986).
Dattwyler et al., Nature, 256:656-657 (1975).
Gershwin et al., The Journal of Immunology, 121:2292-2298 (1978).
Glazier et al., J. Exp. Med., 158:1-8 (1983).
Goidl et al., Developmental of Immunobiology, pp. 35-55 (1979).
Hamel et al., Phenotype and Function of Bone Marrow-Derived T- and Non-T-Cells Activated In Vitro By Alpha-Fetoprotein, In: Biological Activities of Alpha.sub.1 -Fetoprotein (vol. I), Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 167-177 (1987).
Heyward et al., The Lancet, pp. 1161-1162 (1983).
Hooper et al., Human AFP Inhibits Cell Proliferation and NK-Like Cytotoxic Activity Generated in Autologous, But Not In Allogeneic Mixed Lymphoctye Reactions, In: Biological Activities of Alpha.sub.1 -Fetoprotein, (vol. II) Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 183-197 (1989).
Hooper et al., Selective Inhibition Of Murine T-Cell Proliferation And Lymphokine-Activated Natural Killer Cell Function By alpha-Fetoprotein, In: Biological Activities of Alpha.sub.1 -Fetoprotein, (vol. I) Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 153-165 (1987).
Hooper et al., Cellular Immunology, 63:417-425, (1981).
Hooper et al., Oncodevelopmental Biology and Medicine, 3:151-160 (1982).
Hoskin et al., Cellular Immunology, 96:163-174 (1985).
Hoskin et al., Clin. exp. Immunol., 76:262-267 (1989).
Hoskin et al., Analysis Of Pregnancy-Associated Immunoregulatory Pathways, In: Alpha-Fetoprotein and Congenital Disorders, Academic Press, New York, pp. 59-78, (1985).
Innis et al., Archives of Biochemistry and Biophysics, 195:128-135 (1979).
Ishiguro et al., Cancer, 55:156-159 (1985).
Jacobson et al., Cancer Research, 50:415-420 (1990).
Jiang et al., Science, 256:1213-1215 (1992).
Keller et al., Immunosuppressive Properties of AFP: Role of Estrogens, In: Onco-Developmental Gene Expression, Fishman, W.H. and Sell, S. (eds.), Academic Press, Inc. (New York) pp. 287-295 (1976).
Kikutani et al., Advances in Immunology, 51:285-322 (1992).
Line et al., Medical Potential Of AFP As A Tumor Imaging Agent, In: Biological Activities of Alpha.sub.1 -Fetoprotein (vol. 11), Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 139-148 (1989).
Lu et al., The Journal of Immunology, 132:1722-1727 (1984).
Masuda et al., Tumor Biol., 15:175-183 (1994).
Mizejewski, Gerald J., Laboratory Management, (1987).
Morinaga et al., Proc. Natl. Acad. Sci. USA, 80:4604-4608 (1983).
Moro et al., Tumor Biol., 14:116-130 (1993).
Murgita et al., La Ricerca Clin. Lab., 9:327-342 (1979).
Murgita et al., Prog. Allergy, 29:54-133 (1981).
Murgita et al., The Journal of Experimental Medicine, 141:440-452, 269-286 (1975).
Murgita et al., Proc. Natl. Acad. Sci. USA, 75:2897-2901 (1978).
Murgita et al., Clin. exp. Immunol., 33:347-256 (1978).
Murgita et al., Scand. J. Immunol., 5:1215-1220 (1976).
Murgita, Scand. J. Immunol., 5:1003-1014 (1976).
Murgita et al., Nature, 267:257-259 (1977).
Murgita et al., Eur. J. Immunol., 11:957-964 (1981).
Nelson et al., The New England Journal of Medicine, 329:466-471 (1993).
Nishi et al., J. Biochem., 104:968-972 (1988).
O'Neill et al., Oncodevelopmental Biology and Medicine, 3:135-150 (1982).
Peck et al., The Journal of Immunology, 128:1134-1140 (1982).
Peck et al., The Journal of Experimental Medicine, 147:667-683 (1978).
Peck et al., J. Exp. Med., vol. 148(2) pp. 360-372 (1978).
Sell, S., In: Cancer Markers Diagnostic and Developmental Significance, Sell, S., (ed.), Humana Press, Clifton, NJ pp. 249-293 (1980).
Semeniuk et al., Abstract 2799, Experimental Biology 94.TM., Anaheim, CA (1994).
Soto et al., Proc. Natl. Acad, Sci. USA, 77:2084-2087 (1980).
van Oers et al., Journal of Chromatography, 525:59-69 (1990).
van Oers, et al., J. Exp. Med., 170:811-825 (1989).
Villacampa et al., Biochemical and Biophysical Research Communications, 122:1322-1327 (1984).
Yamamoto et al., Life Sciences, 46:1679-1686 (1990).
Giuliani et al., Protein Engineering, 2:605-610 (1989).
Fialova, L. et al. (1991) "Serum levels of trophoblast-specific beta-1-globulin (SP1) and alpha-1-fetoprotein (AFP) in pregnant women with rheumatoid arthritis" Ceskoslovenska Gynekologie 56(3):166-70.
Hooper, D.C. et al. (1982) "Suppresion of primary and secondary autologous mixed lymphocyte reactions by murine alphafetoprotein" Oncodevelopmental. Biol. Med. 3(2-3):151-160.
Grimes Eric
Lau Kawai
McGill University
LandOfFree
Recombinant human alph-fetoprotein as an immunosuppressive agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant human alph-fetoprotein as an immunosuppressive agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human alph-fetoprotein as an immunosuppressive agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652401